JP2020523022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523022A5 JP2020523022A5 JP2019568654A JP2019568654A JP2020523022A5 JP 2020523022 A5 JP2020523022 A5 JP 2020523022A5 JP 2019568654 A JP2019568654 A JP 2019568654A JP 2019568654 A JP2019568654 A JP 2019568654A JP 2020523022 A5 JP2020523022 A5 JP 2020523022A5
- Authority
- JP
- Japan
- Prior art keywords
- expression profile
- gene
- genes
- subject
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims 49
- 108090000623 proteins and genes Proteins 0.000 claims 35
- 238000000034 method Methods 0.000 claims 29
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 21
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 21
- 238000009169 immunotherapy Methods 0.000 claims 17
- 230000019491 signal transduction Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102000000795 Galectin 1 Human genes 0.000 claims 2
- 108010001498 Galectin 1 Proteins 0.000 claims 2
- 102000000802 Galectin 3 Human genes 0.000 claims 2
- 108010001517 Galectin 3 Proteins 0.000 claims 2
- 101000620365 Homo sapiens Protein TMEPAI Proteins 0.000 claims 2
- 102100022429 Protein TMEPAI Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 102100028914 Catenin beta-1 Human genes 0.000 claims 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519711P | 2017-06-14 | 2017-06-14 | |
| US62/519,711 | 2017-06-14 | ||
| US201862629231P | 2018-02-12 | 2018-02-12 | |
| US62/629,231 | 2018-02-12 | ||
| PCT/US2018/037579 WO2018232142A1 (en) | 2017-06-14 | 2018-06-14 | Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020523022A JP2020523022A (ja) | 2020-08-06 |
| JP2020523022A5 true JP2020523022A5 (enExample) | 2021-07-26 |
Family
ID=64660235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568654A Pending JP2020523022A (ja) | 2017-06-14 | 2018-06-14 | 免疫療法に反応する肝細胞癌のクラスの検出および治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11473150B2 (enExample) |
| EP (1) | EP3638695A4 (enExample) |
| JP (1) | JP2020523022A (enExample) |
| CN (1) | CN111164103A (enExample) |
| WO (1) | WO2018232142A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220112564A1 (en) * | 2019-02-14 | 2022-04-14 | Merck Sharp & Dohme Corp. | Gene expression based biomarker of tumor response to pd-1 antagonists |
| IL291748A (en) * | 2019-11-07 | 2022-06-01 | Oncxerna Therapeutics Inc | Classification of growth microenvironments |
| EP3868897A1 (en) * | 2020-02-20 | 2021-08-25 | Worldwide Innovative Network | Method for improving the treatment with immune checkpoint blockade therapy |
| CN113215253B (zh) * | 2020-06-05 | 2022-10-25 | 冠科生物技术(苏州)有限公司 | 用于评估鼠类肿瘤模型中的免疫反应的方法和组合物 |
| CN112530581B (zh) * | 2020-12-03 | 2023-11-21 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的免疫分子分类系统及其应用 |
| CN112735521B (zh) * | 2021-01-22 | 2023-09-22 | 安徽医科大学第一附属医院 | 一种指导选择适用于抗pd-1/pd-l1免疫治疗患者的膀胱癌免疫分类系统 |
| CN113380318B (zh) * | 2021-06-07 | 2023-04-07 | 天津金域医学检验实验室有限公司 | 人工智能辅助流式细胞术40cd免疫表型检测方法及系统 |
| CN117275733A (zh) * | 2023-11-17 | 2023-12-22 | 中日友好医院(中日友好临床医学研究所) | 基于影像组学预测肿瘤免疫状态及治疗反应的方法及装置 |
| WO2025227286A1 (zh) * | 2024-04-28 | 2025-11-06 | 浙江大学医学院附属邵逸夫医院 | 一种识别肝细胞肝癌新亚型的基因模型构建方法及应用 |
| CN118098378B (zh) * | 2024-04-28 | 2024-07-19 | 浙江大学医学院附属邵逸夫医院 | 一种识别肝细胞肝癌新亚型的基因模型构建方法及应用 |
| CN119530396A (zh) * | 2025-01-22 | 2025-02-28 | 中国科学院杭州医学研究所 | 预测肿瘤免疫治疗效果的标志物及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2081442B1 (en) | 2006-10-10 | 2016-08-10 | TrovaGene, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
| WO2009055480A2 (en) | 2007-10-22 | 2009-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tgf-beta gene expression signature in cancer prognosis |
| AU2009257410B2 (en) * | 2008-06-11 | 2014-03-06 | Fudan University | Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
| US20140017227A1 (en) * | 2011-01-14 | 2014-01-16 | Suk Peng Chew | Gene signatures for use with hepatocellular carcinoma |
| US11242564B2 (en) | 2012-07-12 | 2022-02-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| US20150297310A1 (en) * | 2014-04-17 | 2015-10-22 | Georgia Regents Research Institute, Inc. | Methods for selecting a treatment for cancer |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| WO2016109546A2 (en) * | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
-
2018
- 2018-06-14 JP JP2019568654A patent/JP2020523022A/ja active Pending
- 2018-06-14 CN CN201880052676.1A patent/CN111164103A/zh active Pending
- 2018-06-14 WO PCT/US2018/037579 patent/WO2018232142A1/en not_active Ceased
- 2018-06-14 US US16/621,983 patent/US11473150B2/en active Active
- 2018-06-14 EP EP18816865.2A patent/EP3638695A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523022A5 (enExample) | ||
| Wang et al. | FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients | |
| Kidman et al. | Characteristics of TCR repertoire associated with successful immune checkpoint therapy responses | |
| Yarchoan et al. | PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers | |
| Liu et al. | Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer | |
| McGranahan et al. | Cancer chromosomal instability: therapeutic and diagnostic challenges: ‘Exploring aneuploidy: the significance of chromosomal imbalance’review series | |
| Warth et al. | EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype | |
| Torres et al. | Serum cytokine profile in patients with pancreatic cancer | |
| Jung et al. | High tumor mutational burden predicts favorable response to anti-PD-(L) 1 therapy in patients with solid tumor: a real-world pan-tumor analysis | |
| Perea et al. | HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape | |
| Norman et al. | Anti‐kelch‐like 12 and anti‐hexokinase 1: novel autoantibodies in primary biliary cirrhosis | |
| Clinton et al. | Genomic heterogeneity as a barrier to precision oncology in urothelial cancer | |
| Madore et al. | PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L 1 clinical trials | |
| Khoja et al. | Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance | |
| Timperi et al. | Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer | |
| Chan et al. | Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome | |
| Micalizzi et al. | Cancer metastasis through the prism of epithelial‐to‐mesenchymal transition in circulating tumor cells | |
| Fujii et al. | Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers | |
| Qiu et al. | Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine‐based chemotherapy: evidence from 24 studies | |
| Svensson et al. | Accumulation of CCR4+ CTLA-4hi FOXP3+ CD25hi regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells | |
| Torphy et al. | Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma | |
| Richard et al. | Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients | |
| Ferrín et al. | Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility | |
| Zhao et al. | Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma | |
| Ridder et al. | Comprehensive clinicopathologic study of alpha fetoprotein‐expression in a large cohort of patients with hepatocellular carcinoma |